Roche’s Genentech inks deal with Sosei Heptares
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments.
Read Moreby Anna Smith | Jul 17, 2019 | News | 0
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments.
Read Moreby Anna Smith | Jun 10, 2019 | News | 0
The deal was initially signed in November 2015 to research and develop potential new medicines directed at up to ten GPCR targets across multiple therapeutic areas.
Read Moreby Anna Smith | May 29, 2019 | News | 0
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
Read Moreby Selina McKee | Dec 13, 2018 | News | 0
Sosei has announced that the first healthy subject has been dosed with HTL0014242 – a novel small molecule being tested for its ability to slow neurodegeneration.
Read Moreby Selina McKee | Sep 18, 2018 | News | 0
Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation of an unexpected toxicology finding in an animal study involving non-human primates.
Read Moreby Selina McKee | Jan 11, 2018 | News | 0
Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on gastrointestinal disease.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
